Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of early oral versus prolonged intravenous antibiotics for diabetic foot osteomyelitis
ACTRN12612000833864Phase 4Terminated
- Sponsor
- SouthernBiotech
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clindamycin, ciprofloxacin, trimethoprim + sulfamethoxazole, metronidazole, rifampicin and 6 more in diabetic foot osteomyelitis (DFO) (2 arms), sponsored by SouthernBiotech. Primary endpoints: Resolution of osteomyelitis by clinical assessment and Resolution of osteomyelitis by plain X-ray. Started Sep 2012; status: terminated.
02
Drugs
clindamycinciprofloxacintrimethoprim + sulfamethoxazolemetronidazolerifampicin
03
Conditions
diabetic foot osteomyelitis (DFO)
Beyond the preview
Go deeper on ACTRN12612000833864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000833864.